CD19 and non-Hodgkin lymphoma: ALLO-501 and ALLO-715: Developed by Allogene Therapeutics, ALLO-501 is an allogeneic CAR-T therapy targeting CD19, currently under investigation in patients with relapsed or refractory non-Hodgkin lymphoma (NHL).